Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
You may also be interested in...
Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.